Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.
Status:
Not yet recruiting
Trial end date:
2024-02-23
Target enrollment:
Participant gender:
Summary
Epithelial ovarian cancer is the most fatal gynecological malignancy. Despite initial
therapeutic response, the majority of advanced-stage patients relapse and eventually succumb
to chemoresistant disease. The majority of ovarian cancer patients with standardized
treatment, including tumor cell reduction and postoperatively platinum-based combination
chemotherapy, will still experience tumor recurrence and multiple recurrences within 6-18
months.With the increase in the number of recurrences, the intertherapeutic period will
shorten and eventually drug resistance will emerge.The purpose of treatment for recurrent
ovarian cancer is mainly to improve the quality of life of patients and prolong survival.
CSPC OUYI PHARMACEUTICAL CO., LTD has successfully developed Paclitaxel (Albumin-Bound) and
the bioequivalence test results show good consistency with Abraxane.To evaluate the efficacy
and safety of Paclitaxel (Albumin-Bound) combination with carboplatin in Chinese patients
with platinum-sensitive recurrent ovarian cancer, this clinical study is planned.